| BCMA And CD3 Bispecific T Cell Engaging Antibody Constructs |
2023-10-02 |
2023-10-26 |
|
| Insertion mechanism for drug delivery device |
2023-8-03 |
2023-8-24 |
|
| Chimeric receptors and methods of use thereof |
2023-7-24 |
2023-8-17 |
|
| Methods and apparatus for nondestructive detection of undissolved particles in … |
2023-7-23 |
2023-9-01 |
|
| Controllable drug delivery system and method of use |
2023-6-30 |
2023-7-20 |
|
| human CGRP receptor binding protein |
2023-6-21 |
2023-8-22 |
|
| Stabilized receptor polypeptides and uses thereof |
2023-6-07 |
2023-9-21 |
|
| Treatment of asthma with anti-tslp antibody |
2023-5-15 |
2023-7-11 |
|
| Single-use auto-injector |
2023-5-09 |
2023-5-25 |
|
| Compounds that inhibit mcl-1 protein |
2023-5-08 |
2023-8-31 |
|
| Processes of making and crystalline forms of a mdm2 inhibitor |
2023-5-08 |
2023-9-28 |
|
| Rotationally biased insertion mechanism for a drug delivery pump |
2023-5-08 |
2023-8-31 |
|
| Dosing regimen of kras g12c inhibitor |
2023-4-21 |
2023-8-10 |
|
| Dosing of kras inhibitor for treatment of cancers |
2023-4-13 |
2023-7-06 |
|
| Methods for increasing mannose content of recombinant proteins |
2023-4-13 |
2023-8-10 |
|
| System and method for detecting activation of a medical delivery device |
2023-3-29 |
2023-5-04 |
|
| Evolocumab |
2023-3-20 |
2023-3-20 |
|
| Plunger of drug delivery device |
2023-3-14 |
2023-5-30 |
|
| Mammalian cell culture |
2023-3-08 |
2023-7-20 |
|
| Drug delivery device with gear module and related method of assembly |
2023-3-08 |
2023-8-03 |
|
| Drug delivery device with container access system and related method of … |
2023-3-07 |
2023-5-23 |
|
| Reduced viscosity protein pharmaceutical preparation |
2023-2-27 |
2023-4-13 |
|
| Methods for increasing mannose content of recombinant proteins |
2023-2-22 |
2023-6-22 |
|
| Interleukin-2 muteins for expansion of regulatory t cells |
2023-2-10 |
2023-4-12 |
|
| Antigen binding proteins capable of binding thymic stromal lymphopoietin |
2023-2-02 |
2023-5-12 |
|
| Binding effects |
2023-1-31 |
2008-1-30 |
|
| Process for manipulating the level of glycan content of a glycoprotein |
2023-1-18 |
2023-5-25 |
|
| Combination therapy including mdm2 inhibitor and one or more additional … |
2023-1-13 |
2023-3-10 |
|
| Drive mechanisms for drug delivery pumps |
2022-12-28 |
2023-2-02 |
|
| drug delivery device |
2022-12-27 |
2023-3-22 |
|
| Administration of an anti-activin-a compound to a subject |
2022-12-22 |
2023-6-29 |
|
| Drug Delivery Device with Messaging Label |
2022-12-21 |
2023-4-20 |
|
| Systems and approaches for sterilizing a drug delivery device |
2022-12-21 |
2023-4-27 |
|
| Torque driven drug delivery device |
2022-12-20 |
2023-3-07 |
|
| Methods of treating graft versus host disease using il-2 muteins |
2022-12-20 |
2023-5-04 |
|
| Injector and method of assembly |
2022-12-08 |
2023-2-21 |
|
| Drug delivery system with temperature-sensitive control |
2022-12-06 |
2023-3-22 |
|
| Methods for treating crohn's disease using anti-il23 antibody |
2022-11-02 |
2023-1-25 |
|
| Trem2 antigen binding proteins and uses thereof |
2022-10-14 |
2022-12-20 |
|
| Method of treating diseases using an il-17 receptor antibody formulation |
2022-10-11 |
2023-6-22 |
|
| Prediction of clinical response to il23-antagonists using il23 pathway … |
2022-10-03 |
2023-1-10 |
|
| Self-buffering protein formulations |
2022-9-29 |
2022-12-13 |
|
| Inhibitors of kras g12c and methods of using the same |
2022-9-27 |
2022-12-13 |
|
| Salt of omecamtiv mecarbil and process for preparing salt |
2022-9-08 |
2023-2-09 |
|
| Interleukin-21 muteins and methods of treatment |
2022-9-07 |
2022-9-29 |
|
| Drug delivery device and method of manufacture |
2022-9-02 |
2022-9-29 |
|
| Methods for treating or preventing migraine headache |
2022-9-02 |
2023-1-19 |
|
| Salts and crystal forms of omecamtiv mecarbil |
2022-9-02 |
2023-4-06 |
|
| Aqueous Formulation of Erythropoiesis Stimulating Protein Stabilised by … |
2022-9-01 |
2023-4-27 |
|
| Production of glycoproteins using manganese |
2022-8-31 |
2022-12-22 |
|
| Methods For Harvesting Mammalian Cell Cultures |
2022-8-29 |
2022-9-22 |
|
| Btnl3 proteins, nucleic acids and antibodies and uses thereof |
2022-8-23 |
2023-6-22 |
|
| Human CD30 ligand antigen binding proteins |
2022-8-18 |
2022-10-20 |
|
| Lyophilized therapeutic peptibody formulations |
2022-8-18 |
2022-11-01 |
|
| Methods of treating or preventing cholesterol related disorders |
2022-8-11 |
2022-9-29 |
|
| Drug delivery device with activation prevention feature |
2022-8-10 |
2022-10-25 |
|
| Plunger rod and syringe assembly system and method |
2022-8-02 |
2022-10-19 |
|
| Capture Purification Processes for Proteins Expressed in a Non-Mammalian System |
2022-7-27 |
2023-1-19 |
|
| Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
2022-7-26 |
2022-9-01 |
|
| Combination therapy including a kras g12c inhibitor and one or more additional … |
2022-7-21 |
2023-4-20 |
|
| Autoinjector apparatus |
2022-7-20 |
2022-11-03 |
|
| Apj receptor agonist and use thereof |
2022-6-30 |
2022-9-13 |
|
| Pharmaceutical composition comprising bispecific antibody constructs |
2022-6-30 |
2023-4-06 |
|
| Device and method for making aseptic connections |
2022-6-29 |
2022-7-21 |
|
| Method for preparing amg 416 (etelcalcetide) |
2022-6-28 |
2023-3-30 |
|
| Kras g12c inhibitors and methods of using the same |
2022-6-21 |
2022-8-30 |
|
| Syringe adapter and guide for filling an on-body injector |
2022-6-14 |
2022-9-29 |
|
| Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[ … |
2022-6-09 |
2022-6-30 |
|
| Injector and method of assembly |
2022-6-01 |
2022-8-17 |
|
| Chimeric receptors to flt3 and methods of use thereof |
2022-5-23 |
2023-4-20 |
|
| Drug delivery device |
2022-5-18 |
2022-6-09 |
|
| Drug delivery device with live button or user interface field |
2022-5-16 |
2022-9-01 |
|
| Mutant, composition, and method of type 3 tissue inhibitor of metalloprotease ( … |
2022-5-02 |
2022-8-09 |
|
| Autoinjector with shock reducing elements |
2022-5-02 |
2022-7-06 |
|
| Protease-activatable bispecific proteins |
2022-4-22 |
2023-7-06 |
|
| Drug delivery device with sterile fluid flowpath and related method of assembly |
2022-4-21 |
2022-7-06 |
|
| Heterodimeric Bispecific Antibodies |
2022-4-18 |
2023-3-16 |
|
| St2 antigen binding proteins |
2022-4-15 |
2022-7-20 |
|
| V-c-fc-v-c antibody |
2022-3-23 |
2023-2-23 |
|
| Bispecific fc molecules |
2022-3-17 |
2023-7-06 |
|
| Synthesis of key intermediate of kras g12c inhibitor compound |
2022-3-08 |
2022-7-14 |
|
| Drug delivery device |
2022-3-07 |
2022-5-01 |
|
| Antibodies directed to her-3 and uses thereof |
2022-3-04 |
2023-2-23 |
|
| Drug delivery device |
2022-3-01 |
2022-5-01 |
|
| Stabilization of Fc-containing polypeptides |
2022-2-22 |
2022-3-17 |
|
| Binding molecules for bcma and cd3 |
2022-2-15 |
2022-8-11 |
|
| Bisamide sarcomere activating compounds and uses thereof |
2022-2-15 |
2023-10-10 |
2023-10-10 |
| Kras g12c inhibitors and methods of using the same |
2022-1-19 |
2022-6-09 |
|
| Asgr inhibitors |
2022-1-07 |
2022-6-10 |
|
| Solid state forms |
2021-12-23 |
2022-4-12 |
|
| Kif18a inhibitors |
2021-12-14 |
2022-4-07 |
|
| Methods of treatment using an interferon gamma inhibitor |
2021-12-14 |
2022-5-12 |
|
| Apelin polypeptides |
2021-12-10 |
2022-2-16 |
|
| Sclerostin epitopes |
2021-12-01 |
2022-2-08 |
|
| Formulations of human anti-rankl antibodies, and methods of using the same |
2021-11-18 |
2022-5-12 |
|
| Human il-23 antigen binding proteins |
2021-11-12 |
2022-2-24 |
|
| Reducing probability of glass breakage in drug delivery devices |
2021-11-08 |
2022-6-30 |
|
| Process control systems and methods for use with filters and filtration … |
2021-10-27 |
2022-1-14 |
|
| Compounds that inhibit mcl-1 protein |
2021-10-14 |
2023-2-16 |
|
| Bcma and cd3 bispecific t cell engaging antibody constructs |
2021-10-07 |
2022-1-25 |
|